Renaissance Capital logo

Lexeo Therapeutics Priced, Nasdaq: LXEO

Phase 1 biotech developing gene therapies for cardio and neuro diseases.

Industry: Health Care

Latest Trade: $16.20 0.00 (0.0%)

First Day Return: -8.6%

Return from IPO: +47.3%

Industry: Health Care

We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems. Our current pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. Our most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreich’s ataxia, or FA, cardiomyopathy, is currently being evaluated in an ongoing Phase 1/2 clinical trial and we have observed an increase in frataxin protein expression in the heart from one patient in the low dose cohort based on a cardiac biopsy utilizing two separate analyses. We expect to report additional interim data from this trial in mid-2024. Our second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, or ACM, caused by mutations in the PKP2 gene, referred to as PKP2-ACM, received investigational new drug, or IND, clearance from the U.S. Food and Drug Administration, or FDA, in July 2023 and we expect to dose the first patient in a Phase 1/2 clinical trial in the first half of 2024 and provide an interim data readout from cohort 1 in the second half of 2024.
more less
IPO Data
IPO File Date 09/29/2023
Offer Price $11.00
Price Range $13.00 - $15.00
Offer Shares (mm) 9.1
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/02/2023
Offer Price $11.00
Price Range $13.00 - $15.00
Offer Shares (mm) 9.1
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
Leerink Partners
more
Company Data
Headquarters New York, NY, United States
Founded 2017
Employees 53
Website www.lexeotx.com

Lexeo Therapeutics (LXEO) Performance